W.Va.'s bioscience industry sees growth

MORGANTOWN — West Virginia’s bioscience industries are growing rapidly and even outpacing national growth in this arena according to a recently conducted industry-wide study.

The Biotechnology Innovation Organization, a national trade association representing the bioscience industries, conducted a study titled “Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018” which compared the industry in all 50 states, Puerto Rico and the District of Columbia. Its findings concluded that the Mountain State has witnessed expansion in terms of funding, number of firms and employees during the past few years.

Read more: W.Va.'s bioscience industry sees growth

Study Finds West Virginia’s Bioscience Industries Experiencing Strong Growth

Charleston, W.Va. (June 6, 2018) – According to an industry-wide study released on June 5th on the economic impact of the U.S. bioscience industries, “West Virginia’s bioscience industry is growing rapidly...State bioscience firms grew their employment base by 14 percent from 2014 through 2016, well outpacing national growth (4.4 percent) to reach nearly 8,000 total industry jobs”.

The study, entitledInvestment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, was conducted by the Biotechnology Innovation Organization (BIO) – the national trade association representing the bioscience industries.

According to the report:

Read more: Study Finds West Virginia’s Bioscience Industries Experiencing Strong Growth

Bioscience a growing piece of state's economy

Officials from Marshall, West Virginia University and several businesses related to the bioscience industry gathered Thursday at the Brad D. Smith Foundation Hall on Marshall's Huntington campus for the eighth annual West Virginia Bioscience Summit.

"Approximately 7,000 jobs currently exist in the bioscience industry in West Virginia," said Richard Giersch, director of the Health Sciences, Innovation, Entrepreneurship and Commercialization for West Virginia University. "It also has over a dozen startup companies in the last three years or so. It's a robust part of the economy that is small, but is growing."

Read more: Bioscience a growing piece of state's economy

8th Annual West Virginia Bioscience Summit

The Bioscience Association of West Virginia will host the 8th Annual West Virginia Bioscience Summit on Thursday, April 19 at the Brad D. Smith Foundation Hall, on the campus of Marshall University in Huntington, West Virginia.

State and regional leaders - from the life sciences, academia and government - will inform, educate and inspire attendees on a variety of topics, such as the incredible innovation coming out of state biotech companies, university commercialization activities, funding opportunities and much more.  And, stay tuned for prominent keynote presenters to be announced soon!

The event will begin at 10:00 am on Thursday, April 19 and will include a keynote luncheon followed by an afternoon of featured presenters. An agenda will be announced soon.

Register today by clicking here!

Exhibitors

Exhibit space is available but may fill up quickly.  To reserve exhibit space, email Bryan Brown by This email address is being protected from spambots. You need JavaScript enabled to view it..

Sponsorship

Event Sponsorship is being provided by the following: Marshall University, Mylan, BIO, VWR International, WVU Corporate Relations, TechConnectWV, PhRMA, Amgen and the Consumer Healthcare Products Association.  

Additional sponsorships are available.  For additional information, contact Bryan Brown at (304) 546-5500 or via This email address is being protected from spambots. You need JavaScript enabled to view it..

We look forward to seeing you in Huntington on April 19 for the 8th Annual West Virginia Bioscience Summit!

Protea Announces Research Agreement with Mass General Hospital

Morgantown WV USA, 8:00AM ET, August 8  2017 – Protea Biosciences Group, Inc. (OTCQB: PRGB) (“Protea”) announced today that it had entered into a Collaboration Research Agreement with the Vaccine and Immunotherapy Center (VIC), Division of the Massachusetts General Hospital (MGH) and Harvard Medical School. The goal is to co-develop a new diagnostic methodology that will provide cancer cell molecular profiles, including the distribution of drugs within cancer cells and molecular response indicators, to improve patient treatment and outcomes.

“This is a very exciting opportunity for our scientists at VIC to gain access to an advanced molecular imaging technology and collaborate with Protea’s scientists to bring that technology to clinical relevance for our patients”, stated Mark Poznansky, M.D., Ph.D., Director of the MGH Vaccine and Immunotherapy Center and the Principal Investigator for the joint research program.


“We are delighted to be undertaking the development of this groundbreaking diagnostic technology with the VIC Team”, commented Steve Turner, Protea Chairman & CEO. He added, “Our collective goal is to improve the molecular information rapidly available to patients and their physicians from tumor samples, which can be used as the basis for decisions regarding both the initiation and modification of specific immunotherapies for their treatment”.

Immunotherapy is a type of cancer treatment that boosts the body's natural defenses to fight the cancer. It uses substances made by the body or in a laboratory to improve or restore the function of the body’s natural immune system. Immunotherapies can alter the immune environment of the tumor, leading to better therapeutic outcome. The total Immunotherapy market is estimated to be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade,

Immunotherapies are increasingly being integrated into treatments for solid tumors - drugs that have great promise for some patients but are expensive and come with some significant adverse events. However currently, standard clinical measurements only provide serum levels of drug and provide little or no information on changes within the tumor. Patients currently undergo costly therapy with significant potential side effects but without a robust means to evaluate the impact of the therapy in the tumor microenvironment. For new immunotherapies to have maximum impact in a cost-effective way, it will be essential to generate more molecular information from tumor samples that can support medical decision making at the start of, and throughout the process of, treatment of the cancer. Developing the technology to provide this molecular information is the goal of this joint research collaboration.

About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical and life science industries. The Company has developed next gen technology that enables the rapid and direct identification, mapping and display of the molecules present in all living cells and tissue samples. Protea applies its technology to the development of new molecular tests for the differential diagnosis of cancer, and the comprehensive molecular profiling of human disease.

"Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. The company provides proprietary molecular information services to its clients in the pharmaceutical and life science industries. 

Forward-Looking StatementsThis press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more Information:

Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA

Phone:  304.292.2226http://proteabio.com/investor-Company-Profile.html

This email address is being protected from spambots. You need JavaScript enabled to view it.

Protea is a registered trademark of Protea Biosciences Group, Inc

Press Archive